ImmuneWalk Therapeutics
Rehovot, Israel· Est.
ImmuneWalk pioneers adhesion‑checkpoint blockade to prevent immune‑cell infiltration in inflammatory disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
ImmuneWalk pioneers adhesion‑checkpoint blockade to prevent immune‑cell infiltration in inflammatory disorders.
ImmunologyInflammatory Diseases
Technology Platform
ImmuneWalk has identified a novel adhesion checkpoint that regulates monocyte and neutrophil trafficking into inflamed tissues; its monoclonal antibody IW‑601 blocks this checkpoint, preventing immune cell infiltration.
Opportunities
First‑in‑class anti‑inflammatory approach targeting immune‑cell migration could address unmet needs across both common and rare inflammatory diseases.
Risk Factors
Clinical efficacy and safety in humans remain unproven; competition from established anti‑cytokine biologics and regulatory hurdles could delay development.
Competitive Landscape
Differentiates from cytokine blockers by modulating cell trafficking, though faces competition from agents like anti‑integrin and anti‑selectin antibodies.